Home » Blog » Exciting New Research and Treatments for Leukemia

Exciting New Research and Treatments for Leukemia

IP Blog | Dave Melin | July 9, 2017

BioBlog Weekly oncologyIn this week’s BioBlog we look into several new studies for Acute Myeloid Leukemia, along with promising new drugs to help treat and reduce relapse occurrence in AML patients.

Stem-Cell Researchers Solve Mystery of Relapse in Acute Myeloid Leukemia

Scientists have identified a specific type of stem-cell that is present at the time of diagnosis that makes certain AML patients resistant to different therapies.

Positive New Data for Ceplene in Acute Myeloid Leukemia

In a recent clinical trial the drug Ceplene showed positive results in preventing relapse in AML patients.

No Difference in Survival for Idarubicin, High-Dose Daunorubicin in AML

A look at recent studies that have examined the effectiveness of using Idarubicin and Daunorubicin as a course of treatment for AML.

Midostaurin Improves Survival in Acute Myeloid Leukemia With FLT3 Mutation

A study published by the New England Journal of Medicine using Midostaurin in conjunction with chemotherapy found that is provided a significant benefit to the survival of AML patients with the FLT3 mutation.

Favorable Safety Profile Observed in Phase 1 Study of Acute Myeloid Leukemia Drug

Phase 1 of a new AML drug study shows that it it has the desired safety and it shows signs of tolerability in patients in varying dosage levels.

Topics in this Post:

Leave a Comment

Your email address will not be published. Required fields are marked *